Psychopharmacology

, Volume 91, Issue 1, pp 90–95 | Cite as

Senile dementia of the Alzheimer type treated with aniracetam: a new nootropic agent

  • Leif B. Sourander
  • Raija Portin
  • Pekka Mölsä
  • Anne Lahdes
  • Urpo K. Rinne
Original Investigations

Abstract

Forty-four patients with senile dementia of the Alzheimer type were randomly allocated into double-blind treatment with either aniracetam (RO 13-5057) 1 g or placebo daily for 3 months. Neurological examinations were made before and after treatment and psychometric tests were performed before and after 1 month's and after 3 month's treatment. Treatment was interrupted due to occurrence of confusion in four cases in the aniracetam group and in one case in the placebo group. During treatment, an improvement was seen in several cognitive tests, especially those associated with memory, but this improvement occurred in the placebo as well as in the aniracetam-treated group. In clinical evaluation no difference was seen in efficacy between the two treatment groups.

Key words

Senile dementia of the Alzheimer type Aniracetam Nootropic agent 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Benton P (1963) The revised visual retention test. The Psychological Corporation, New YorkGoogle Scholar
  2. Canter GJ, La Torre R de, Mier M (1961) A method for evaluating disability in patients with Parkinson's disease. J Nerv Ment Dis 133:143–147Google Scholar
  3. Christensen AL (1974) Luria's Neuropsychological Investigation. Munksgaard, CopenhagenGoogle Scholar
  4. Dajas F, Romero S, Florens M, Lorenzo J et al. (1983) Neuropsychological and psychiatric assessment of the effects of aniracetam (RO 13-5057) on age related brain deficits. Preliminary results. Presented at the 6th Int Neuropsychological Soc (INS) Eur Conf, Lisbon, 14–17 June, 1983. The InS Bulletin, p 12Google Scholar
  5. Giurgea C, Lefevre D, Lercrenier C, David-Remade M (1971) Pharmacological protection against hypoxia-induced amnesia in rats. Psychopharmacologica 20:160–168Google Scholar
  6. Hachinski VC, Iliff LD, Zilkha E, Du Bowlay GH, McAllister VL, Marshall J, Ross-Russell RW, Symon L (1975) Cerebral blood flow in dementia. Arch Neurol 32:632–637Google Scholar
  7. Jarho L (1973) Korsakoff-like amnesic syndrome in penetrating brain injury. A study of Finnish war veterans. Acta Neurol Scand 49:Suppl 54Google Scholar
  8. Lagergren K, Levander S (1974) A double-blind study on the effects of piracetam upon perceptual + psychomotor performance at varied heart rates in patients with artificial pace-makers. Psychopharmacologica 39:97–104Google Scholar
  9. Lezak MD (1976) Neuropsychological Assessment. O.U.P., New YorkGoogle Scholar
  10. Loew DM, Weil C (1982) Hydergine in senile mental impairment. Gerontology 28:54–74Google Scholar
  11. Portin R, Rinne UK (1980) Neuropsychological responses of parkinsonian patients to long-term levodopa treatment. In: Rinne UK, Kingler M, Stamm G (eds) Parkinson's disease — current progress, problems and management. Elsevier, North Holland Biomedical Press, pp 271–304Google Scholar
  12. Portin R, Rinne UK (1983) The effect of deprenyl on cognition and emotion in parkinsonian patients with long-term levodopa treatment. Acta Neurol Scand 68:Suppl 95; 135–144Google Scholar
  13. Rinne UK, Sonninen V (1968) A double-blind study ofl-dopa treatment in Parkinson's disease. Eur Neurol 1:180–191Google Scholar
  14. Saletu B, Grunberger J, Linzmayer L (1980) Quantitative EEG and psychometric analyses in assessing CNS-activity of Ro 13-5057 — a cerebral insufficiency improver. Methods Find Exp Clin Pharmacol 2(5):269–285Google Scholar
  15. Shader RJ, Harmatz JS, Salzman C (1974) A new scale for clinical assessments in geriatric populations. Sandoz clinical assessment geriatric (SCAG). J Am Geriatr Soc 22:107–113Google Scholar
  16. Wechsler D (1981) Wechsler Adult Intelligence Scale — revised. The Psychological Corporation, New YorkGoogle Scholar
  17. Wells PL, Reusch J (1945) Mental examiner's handbook. Revised edition. The Psychological Corporation, New YorkGoogle Scholar
  18. Wolthuis OL (1971) Experiments with UCB 6125, a drug which enhances acquisition in rats. Its effects compared with those of metanphetamine. Eur J Pharmacol 16:283–297Google Scholar
  19. Zung WWK (1965) A self-rating depression scale. Arch Gen Psychiatry 12:63–70Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • Leif B. Sourander
    • 1
  • Raija Portin
    • 2
  • Pekka Mölsä
    • 2
  • Anne Lahdes
    • 2
  • Urpo K. Rinne
    • 2
  1. 1.Department of Internal MedicineTurku City HospitalTurkuFinland
  2. 2.Department of NeurologyTurku University Central HospitalTurkuFinland

Personalised recommendations